DYNAMIC BIOSYSTEMS Acquires SEERNA BIOSCIENCE to Build a World-Class Single-Cell and Spatial Multi-Omics Product Portfolio

Recently, Dynamic Biosystems (hereinafter referred to as “Dynamic Biosystems”) announced the completion of its acquisition of Seerna Bioscience (hereinafter referred to as “Seerna Bioscience”), thereby integrating an internationally leading spatial multi-omics platform into its proprietary product pipeline spanning single-cell enrichment, single-cell sequencing, and spatial transcriptomics.

After integration, Dynamic BiosystemsWill become the world’s only biotechnology company to possess both end-to-end single-cell sequencing capabilities (single-cell enrichment, trace/ultra-high-throughput single-cell sequencing) and end-to-end spatial multi-omics technologies (in situ capture spatial omics, in situ hybridization, and in situ sequencing)., poised to establish a globally leading Chinese enterprise in single-cell and spatial multi-omics at the forefront of global life sciences, thereby creating unprecedented biomedical value.

Spatial multi-omics was listed by Nature as one of the seven technologies to watch in 2022. Single-cell sequencing has become an indispensable and powerful tool in biomedicine by efficiently detecting gene expression heterogeneity across different cells. In recent years, spatial omics technologies have advanced further, preserving spatial location information while analyzing distinct cell subpopulations, thereby providing critical insights into cellular functions, phenotypes, and positional relationships within the tissue microenvironment.

Today, single-cell and spatial multi-omics technologies are widely applied in fields such as oncology, immunology, neuroscience, reproductive biology, and drug development, driving successive waves of revolution in both basic and clinical medical technologies. It is reported that at the J.P. Morgan Healthcare Conference in January 2022, 10x Genomics, the global leader in single-cell sequencing, announced its plan to launch the commercial platform for Xenium In Situ Analysis technology in 2023, following the release of its Visium spatial transcriptomics platform based on in situ capture technology in 2020. This announcement has sparked significant academic interest and commercial anticipation.

Upon completion of this merger and acquisition,Dynamic Biosystems possesses a complete suite of spatial omics technologies with independent intellectual property rights, including RNA in situ capture, in situ sequencing, and in situ hybridization.In situ capture spatial omics technologies are characterized by high throughput, enabling the discovery of potential spatial heterogeneity in gene expression. In situ sequencing (ISS) offers medium throughput, allowing for the simultaneous detection and analysis of hundreds of genes with single-cell or even subcellular resolution. Meanwhile, in situ hybridization (ISH) provides the highest resolution, facilitating precise spatial localization of the expression of identified target genes.

Professor Ke Rongqin, Founder and Chief Scientist of Xianneng Biology, earned his Ph.D. in Medical Sciences from Uppsala University in Sweden in 2012. As one of the inventors of RNA in situ sequencing technology, he published the paper “In situ sequencing for RNA analysis in preserved cells and tissue” as the first author in Nature Methods (2013, 10: 857–860). This technology was selected that same year as a notable new method among Nature Methods’ Methods to Watch.

After earning his Ph.D., Professor Rongqin Ke was invited to join Complete Genomics, a renowned next-generation sequencing (NGS) company based in California, USA, as a Senior Scientist. During his tenure, he served as a core member of the team deeply involved in the research and development of novel NGS and related molecular diagnostic technologies. The paired-end sequencing technology based on DNA nanoballs, which he invented, has become one of the core technologies underlying BGI’s independently developed domestic NGS systems. In 2016, Dr. Ke returned to China under the Young Overseas High-Level Talent Introduction Plan. He assumed the positions of Distinguished Professor and Doctoral Supervisor at the Medical College of Huaqiao University, and founded Xianneng Biology in 2019. A paper describing the application of his latest technology, recognized as the first article from China on in situ RNA sequencing, was published in Nature Neuroscience (Impact Factor: 24.884) in November 2021.

Professor Yang Chaoyong, Founder, Chairman, and Chief Scientist of Dynamic Biosystems, stated, “Under the leadership of Professor Ke, XianNeng Bio’s in situ spatial omics technology has achieved world-class standards through years of technological accumulation and continuous innovation. It complements Dynamic Biosystems’ single-cell and spatial omics technologies, enabling us to provide more comprehensive services and solutions for the life sciences and medical fields, ultimately delivering transformative diagnostic technologies to patients in clinical settings. The fundamental reason for the successful partnership between Dynamic Biosystems and XianNeng Bio lies in our shared commitment to developing foundational technologies at the forefront of global science, our dedication to R&D innovation as the core driver of corporate growth, and our unwavering original aspiration to strive for China’s scientific self-reliance and break through foreign technological bottlenecks.”

Professor Rongqin Ke stated, “We are delighted to join forces with Professor Chaoyong Yang’s team, combining our years of accumulated expertise in in situ spatial technologies with Dynamic Biosystems’ single-cell and spatial omics capabilities. This strategic partnership will create maximum synergistic value for both parties in talent development, technological innovation, and commercialization, while providing scientists and enterprises worldwide with a comprehensive end-to-end solution for ‘single-cell multi-omics plus spatial multi-omics.’ Spatial multi-omics technology represents a perfect integration of histopathology and molecular biology. By consolidating our R&D teams, we will work together to compete with international peers and accelerate the launch of China’s independently developed automated in situ sequencing instruments and supporting reagent kits.”

Li Jiacheng, CEO of Dynamic Biosystems, stated: “By the end of 2021, Xianneng Biology had already launched commercialized next-generation single-molecule RNA chromogenic in situ hybridization (smCISH) kits, singleplex and multiplex RNA fluorescence in situ hybridization (FISH) kits, as well as in situ transcriptome sequencing services. Among these, the highly multiplexed RNA in situ sequencing technology offers subcellular resolution and features advantages such as larger tissue area analysis, lower costs, and shorter analysis times. It has successfully provided high-quality research services to numerous scientific teams. Beyond supporting academic research, these products and technologies hold significant potential for drug development and clinical pathology translation. We will increase our investment in and commercial promotion of in situ sequencing technologies, with plans to gradually introduce internationally competitive products into overseas and clinical markets within two years. Following the integration, Dynamic Biosystems boasts a ‘powerhouse combination’ in the fields of single-cell and spatial multi-omics, which will greatly enhance the company’s innovation leadership and international competitive advantage.”

Dynamic Biosystems (http://www.dynamic-biosystems.com) is a technology platform company specializing in single-cell and spatial multi-omics. Centered on single-cell enrichment and detection, single-cell sequencing, and spatial multi-omics technologies, the company meets analytical needs across diverse application scenarios. It focuses on unlocking significant potential in precision oncology, eugenics and healthy reproduction, and drug discovery. Committed to advancing precision medicine into the era of single-cell and spatial omics, Dynamic Biosystems supports life sciences and clinical medicine, contributing Chinese expertise to the cause of human health.

Xiamen Seerna Biotechnology Co., Ltd. (http://www.seerna.com) is one of the few emerging technology platform companies in China currently focused on single-molecule RNA in situ detection and analysis. Adhering to frontier technology-driven development, the company strives to apply its significant technological achievements and breakthroughs to the fields of basic biology, translational medicine, and clinical diagnostics, establishing a comprehensive scientific platform that integrates product development and testing services. Committed to integrity, focus, innovation, and pioneering spirit, we dedicate ourselves to providing customers with high-quality and reliable products and services.